2-(1H-indazol-5-ylmethyl)succinic acid 1-methyl ester | 635713-15-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 2-(1H-indazol-5-ylmethyl)succinic acid 1-methyl ester
• 英文别名: methyl 2-(1H-indazol-5-ylmethyl)-succinate；3-(1H-indazol-5-ylmethyl)-4-methoxy-4-oxobutanoic acid
• CAS: 635713-15-4
• 化学式: C₁₃H₁₄N₂O₄
• 分子量: 262.265
• InChiKey: GQRSVTOKENGEPQ-UHFFFAOYSA-N

物化性质

• 沸点：
  497.8±35.0 °C(Predicted)
• 密度：
  1.362±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  92.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(1H-indazol-5-ylmethyl)succinic acid 1-methyl ester 在 三乙胺 、 3-(二乙氧基邻酰氧基)-1,2,3-苯并三嗪-4-酮 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 (+/-)-1-[1,4']bipiperidinyl-1'-yl-2-(1H-indazol-5-ylmethyl)-4-[1',2'-dihydro-2'-oxospiro-4H-3',1-benzoxazine-4,4'-piperidinyl]-butane-1,4-dione
  参考文献：
  名称：

  Calcitonin gene-related peptide (CGRP) receptor antagonists: Novel aspartates and succinates

  摘要：

  Novel aspartate and succinate CGRP full antagonists were identified through core modification of a potent lead CGRP antagonist, BMS-694153. While aspartates were much less active and had a flat SAR, some of the succinates were very potent CGRP full antagonists and matched the potency of BMS-694153. The most potency resides in the S enantiomer as demonstrated through an asymmetric synthesis. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.066
• 作为产物：
  描述：

  丁二酸二甲酯 在 palladium on activated charcoal 、 potassium tert-butylate 、 氢气 作用下， 以 甲醇 、 乙酸乙酯 、 叔丁醇 为溶剂， 生成 2-(1H-indazol-5-ylmethyl)succinic acid 1-methyl ester
  参考文献：
  名称：

  Calcitonin gene-related peptide (CGRP) receptor antagonists: Novel aspartates and succinates

  摘要：

  Novel aspartate and succinate CGRP full antagonists were identified through core modification of a potent lead CGRP antagonist, BMS-694153. While aspartates were much less active and had a flat SAR, some of the succinates were very potent CGRP full antagonists and matched the potency of BMS-694153. The most potency resides in the S enantiomer as demonstrated through an asymmetric synthesis. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.066

文献信息

• [DE] AUSGEWÄHLTE CGRP-ANTAGONISTEN, VERFAHREN ZU DEREN HERSTELLUNG SOWIE DEREN VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] SELECTED CGRP-ANTAGONISTS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS<br/>[FR] ANTAGONISTES DE CGRP SELECTIONNES, PROCEDES DE FABRICATION ET UTILISATION EN TANT QUE MEDICAMENT
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2005084672A1

  公开（公告）日：2005-09-15

  Die vorliegende Erfindung betrifft substituierte Piperidine der allgemeinen Formel (I), in der A, B, D, E, X, R1 und R2 wie in Anspruch 1 definiert sind, deren Tautomere, deren Diastereomere, deren Enantiomere, deren Hydrate, deren Gemische und deren Salze sowie die Hydrate der Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung.

  本发明涉及一般式（I）中的取代哌啶，其中A、B、D、E、X、R1和R2如权利要求1中所定义的它们的互变异构体，对映异构体，单一异构体，水合物，混合物和其盐，特别是其与无机或有机酸形成的生理相容盐，以及含有这些化合物的药物、其使用和制备方法。
• Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions
  申请人：Lustenberger Philipp

  公开号：US20050227968A1

  公开（公告）日：2005-10-13

  The present invention relates to substituted piperidines of general formula wherein A, B, D, E, X, R 1 and R 2 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

  本发明涉及通式所示的取代哌啶，其中A，B，D，E，X，R1和R2如权利要求书1所定义的那样，其互变异构体，对映异构体，立体异构体，其水合物，其混合物和其盐及其盐的水合物，特别是其与无机或有机酸的生理上可接受的盐，以及含有这些化合物的制药组合物，其使用和其制备方法。
• US7205294B2
  申请人：——

  公开号：US7205294B2

  公开（公告）日：2007-04-17
• Calcitonin gene-related peptide (CGRP) receptor antagonists: Novel aspartates and succinates
  作者：Guanglin Luo、Ling Chen、Sokhom S. Pin、Cen Xu、Charles M. Conway、John E. Macor、Gene M. Dubowchik

  DOI：10.1016/j.bmcl.2012.02.066

  日期：2012.4

  Novel aspartate and succinate CGRP full antagonists were identified through core modification of a potent lead CGRP antagonist, BMS-694153. While aspartates were much less active and had a flat SAR, some of the succinates were very potent CGRP full antagonists and matched the potency of BMS-694153. The most potency resides in the S enantiomer as demonstrated through an asymmetric synthesis. (C) 2012 Elsevier Ltd. All rights reserved.